beta
Trial Radar AI

Showing clinical trials matching location: California.

I can help you find nearby clinical trials and understand health conditions and treatments.
63 Results
Top 50 Showing
 
Status (Default)
Not yet Recruiting, Recruiting, Active, Not Recruiting
×
 
Location
California
×
 
Intervention
GLP-1
×
 
Study Title
Status
Assess Impact of Poly-L-lactic Acid on GLP1 Subjects NCT07217743
Not yet recruiting
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists NCT07221461
Not yet recruiting
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists NCT07224880
Recruiting
Restoring Facial Volume After GLP-1 Weight Loss With Radiesse NCT07419854
Recruiting
Stanford Pediatric Healthy Weight Index NCT07316816
Recruiting
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1) NCT06867718
Active, not recruiting
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight (VESPER-1) NCT06712836
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM (VESPER-2) NCT06897202
Active, not recruiting
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants NCT06737042
Not yet recruiting
Avexitide for Treatment of Post-Bariatric Hypoglycemia (LUCIDITY) NCT06747468
Active, not recruiting
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide (REMAIN-1) NCT06484114
Active, not recruiting
VK2735 for Weight Management Phase 3 (VANQUISH 1) NCT07104500
Active, not recruiting
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) NCT07104383
Recruiting
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese NCT06732245
Not yet recruiting
Tirzepatide for Alcohol Use Disorder NCT06994338
Recruiting
A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs NCT07437911
Recruiting
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention NCT06682351
Not yet recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy NCT07502508
Recruiting
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) NCT07225816
Recruiting
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes NCT06924320
Recruiting
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial NCT07505303
Not yet recruiting
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes NCT07284901
Recruiting
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes NCT07284979
Recruiting
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes NCT07284875
Recruiting
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB) NCT06651177
Recruiting
Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease (DEFINE-DM) NCT05831085
Recruiting
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (EVOLVE-2) NCT07281937
Active, not recruiting
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight NCT06987513
Active, not recruiting
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity NCT06373146
Active, not recruiting
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (ACCESS II) NCT06703021
Active, not recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) NCT07165028
Recruiting
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (ACCESS) NCT06693843
Active, not recruiting
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial NCT07202247
Recruiting
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. (STARS extend) NCT05018286
Active, not recruiting
Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging NCT07216352
Not yet recruiting
Effects of GRA in Patients With Type 1 NCT04779645
Active, not recruiting
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years NCT07455825
Recruiting
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes (SOTA) NCT05696366
Recruiting
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO) NCT06588283
Active, not recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD) NCT06937099
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC) NCT06937086
Recruiting
The Long COVID Treatment Trial (LOCITT) NCT07128082
Active, not recruiting
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease NCT06976853
Recruiting
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity (GYMINDA) NCT06965413
Active, not recruiting
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2) NCT06962280
Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) NCT06914895
Active, not recruiting
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) NCT06864026
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) NCT06857942
Recruiting
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) NCT06662383
Active, not recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor NCT06221969
Active, not recruiting